IL277779A - Preparations and methods for the treatment of macular degeneration - Google Patents

Preparations and methods for the treatment of macular degeneration

Info

Publication number
IL277779A
IL277779A IL277779A IL27777920A IL277779A IL 277779 A IL277779 A IL 277779A IL 277779 A IL277779 A IL 277779A IL 27777920 A IL27777920 A IL 27777920A IL 277779 A IL277779 A IL 277779A
Authority
IL
Israel
Prior art keywords
compositions
methods
macular dystrophy
treating macular
treating
Prior art date
Application number
IL277779A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Oxford Innovation Ltd
Nightstarx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd, Nightstarx Ltd filed Critical Univ Oxford Innovation Ltd
Publication of IL277779A publication Critical patent/IL277779A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Manufacturing & Machinery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL277779A 2018-04-05 2020-10-04 Preparations and methods for the treatment of macular degeneration IL277779A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862653131P 2018-04-05 2018-04-05
PCT/US2019/026062 WO2019195727A1 (en) 2018-04-05 2019-04-05 Compositions and methods for treating macular dystrophy

Publications (1)

Publication Number Publication Date
IL277779A true IL277779A (en) 2020-11-30

Family

ID=66223872

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277779A IL277779A (en) 2018-04-05 2020-10-04 Preparations and methods for the treatment of macular degeneration

Country Status (21)

Country Link
US (2) US20190307900A1 (enExample)
EP (1) EP3775233A1 (enExample)
JP (1) JP2021520232A (enExample)
KR (1) KR20210005040A (enExample)
CN (1) CN113056561A (enExample)
AU (1) AU2019247864A1 (enExample)
BR (1) BR112020020204A2 (enExample)
CA (1) CA3096088A1 (enExample)
CL (1) CL2020002561A1 (enExample)
CO (1) CO2020013690A2 (enExample)
EA (1) EA202092069A1 (enExample)
IL (1) IL277779A (enExample)
JO (1) JOP20200253A1 (enExample)
MA (1) MA52199A (enExample)
MX (1) MX2020010477A (enExample)
PE (1) PE20210918A1 (enExample)
PH (1) PH12020551641A1 (enExample)
RU (1) RU2020132890A (enExample)
SG (1) SG11202009759SA (enExample)
TW (1) TW202003052A (enExample)
WO (1) WO2019195727A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020047476A1 (en) * 2018-08-31 2020-03-05 University Of Florida Research Foundation, Incorporated Adeno-associated viral vectors for the treatment of best disease
EP3870148A4 (en) 2018-10-25 2022-11-09 Takeda Pharmaceutical Company Limited AAV TRIPLE PLASMID SYSTEM
WO2020140007A1 (en) * 2018-12-28 2020-07-02 University Of Rochester Gene therapy for best1 dominant mutations
BR112022017182A2 (pt) * 2020-02-28 2022-11-08 Univ Pennsylvania Tratamento de bestrofinopatias autossômicas recessivas e métodos para avaliação das mesmas
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用
WO2024064608A2 (en) * 2022-09-20 2024-03-28 Intergalactic Therapeutics, Inc. Best1 vectors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009153563A1 (en) * 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
CA2930282C (en) * 2013-11-20 2024-09-10 Universita Degli Studi Di Napoli Federico Ii Artificial DNA-Binding Proteins and Their Uses
KR102281881B1 (ko) * 2013-12-06 2021-07-27 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) 대상체의 망막 색소 상피에서 목적 폴리뉴클레오티드를 발현시키기 위한 방법 및 약학적 조성물
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
CA2979120A1 (en) * 2015-03-03 2016-09-09 Fondazione Telethon Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof
EP3374494A4 (en) * 2015-11-11 2019-05-01 Coda Biotherapeutics, Inc. CRISPR COMPOSITIONS AND METHODS OF USE THEREOF FOR GENE THERAPY

Also Published As

Publication number Publication date
EP3775233A1 (en) 2021-02-17
AU2019247864A1 (en) 2020-10-22
WO2019195727A1 (en) 2019-10-10
MA52199A (fr) 2021-02-17
BR112020020204A2 (pt) 2021-01-19
PE20210918A1 (es) 2021-05-19
US20190307900A1 (en) 2019-10-10
JP2021520232A (ja) 2021-08-19
PH12020551641A1 (en) 2021-07-26
US20230149566A1 (en) 2023-05-18
MX2020010477A (es) 2021-03-02
JOP20200253A1 (ar) 2020-10-04
CL2020002561A1 (es) 2021-04-23
SG11202009759SA (en) 2020-10-29
CN113056561A (zh) 2021-06-29
RU2020132890A (ru) 2022-05-06
KR20210005040A (ko) 2021-01-13
TW202003052A (zh) 2020-01-16
CA3096088A1 (en) 2019-10-10
CO2020013690A2 (es) 2021-04-19
EA202092069A1 (ru) 2021-03-12

Similar Documents

Publication Publication Date Title
ZA202006627B (en) Methods and compositions for treating cancer
IL264034A (en) Crispr/cas9-based compositions and methods for treating cancer
IL267247B (en) Compositions and methods for treating cancer
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
IL278004A (en) Methods and preparations for treating conditions related to aging
IL274837A (en) Methods and preparations for the treatment of cancer
SG11202009759SA (en) Compositions and methods for treating macular dystrophy
EP3687524A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF OPHTHALMIC DISORDERS
IL285886A (en) Preparations and methods for the treatment of laminopathy
EP3697920A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION
IL271256A (en) Preparations and methods for the treatment of teopathy
IL325803A (en) Compositions and methods for treating cancer
ZA202101362B (en) Compositions and methods for treating the eye
SG11202012435UA (en) Compositions and methods for treating cancer
IL285796A (en) Methods and preparations for the treatment of cancer
SG11201606101WA (en) Compositions and methods for treating and preventing macular degeneration
ZA202101342B (en) Compositions and methods for treating the eye
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
SI3386507T1 (sl) Postopki in sestavki za zdravljenje gastričnih razjed
IL277463A (en) Vehicles and methods for treating itch
ES3065670T3 (en) Compositions and method for treating depression
EP3883588A4 (en) COMPOSITIONS AND METHODS FOR TREATING ENDOMETRIOSIS
IL282948B2 (en) Cancer treatment preparations and methods
EP3262065A4 (en) Methods and compositions for treating dystroglycanopathy disorders